Relevant bibliographies by topics / Pharmacoepidemiology Australia

Academic literature on the topic 'Pharmacoepidemiology Australia'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmacoepidemiology Australia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmacoepidemiology Australia"

1

Hollingworth, Samantha, Kimitra Walker, Andrew Page, and Mervyn Eadie. "Pharmacoepidemiology and the Australian regional prevalence of multiple sclerosis." Multiple Sclerosis Journal 19, no. 13 (March 25, 2013): 1712–16. http://dx.doi.org/10.1177/1352458513482371.

Full text
Abstract:
Background: Over some 50 years, field surveys have shown that the prevalence of multiple sclerosis (MS) increases with increasing distance from the equator in both the northern and the southern hemispheres. Such a latitudinal gradient has been found in field surveys of MS prevalence carried out at different times in various local regions of Australia. Objective: The objective of this paper is to use a pharmacoepidemiological approach to obtain whole of population estimates of the prevalence of MS in the various Australian states and territories from the use of MS disease-modifying drugs used to treat relapsing–remitting MS (RRMS). Methods: We analysed the dispensed use of subsidised RRMS drugs by jurisdiction. Results: In the 2005–2008 period, the calculated mean treated RRMS prevalence in Australia ranged from 7.5 per 100,000 in the far north to 53.2 per 100,000 in the extreme south and was linearly related to increasing southerly latitude. Public domain Australian data suggested that multiplying this prevalence by a factor of 2.2 (to account for untreated RRMS and other types of MS) may provide a measure of the prevalence of all varieties of the disease. Conclusion: These findings provide contemporary and more comprehensive evidence for the gradient of MS prevalence with latitude in Australia than has previously been available.
APA, Harvard, Vancouver, ISO, and other styles
2

Handelsman, David J. "Pharmacoepidemiology of testosterone prescribing in Australia, 1992–2010." Medical Journal of Australia 196, no. 10 (June 2012): 642–45. http://dx.doi.org/10.5694/mja11.11277.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fitzgerald, Stephen P. "Pharmacoepidemiology of testosterone prescribing in Australia, 1992–2010." Medical Journal of Australia 197, no. 6 (September 2012): 329–30. http://dx.doi.org/10.5694/mja12.11014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Herriot, Peter M. "Pharmacoepidemiology of testosterone prescribing in Australia, 1992–2010." Medical Journal of Australia 197, no. 6 (September 2012): 330. http://dx.doi.org/10.5694/mja12.11032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pearson, Sallie-Anne, Nicole Pratt, Juliana de Oliveira Costa, Helga Zoega, Tracey-Lea Laba, Christopher Etherton-Beer, Frank M. Sanfilippo, et al. "Generating Real-World Evidence on the Quality Use, Benefits and Safety of Medicines in Australia: History, Challenges and a Roadmap for the Future." International Journal of Environmental Research and Public Health 18, no. 24 (December 18, 2021): 13345. http://dx.doi.org/10.3390/ijerph182413345.

Full text
Abstract:
Australia spends more than $20 billion annually on medicines, delivering significant health benefits for the population. However, inappropriate prescribing and medicine use also result in harm to individuals and populations, and waste of precious health resources. Medication data linked with other routine collections enable evidence generation in pharmacoepidemiology; the science of quantifying the use, effectiveness and safety of medicines in real-world clinical practice. This review details the history of medicines policy and data access in Australia, the strengths of existing data sources, and the infrastructure and governance enabling and impeding evidence generation in the field. Currently, substantial gaps persist with respect to cohesive, contemporary linked data sources supporting quality use of medicines, effectiveness and safety research; exemplified by Australia’s limited capacity to contribute to the global effort in real-world studies of vaccine and disease-modifying treatments for COVID-19. We propose a roadmap to bolster the discipline, and population health more broadly, underpinned by a distinct capability governing and streamlining access to linked data assets for accredited researchers. Robust real-world evidence generation requires current data roadblocks to be remedied as a matter of urgency to deliver efficient and equitable health care and improve the health and well-being of all Australians.
APA, Harvard, Vancouver, ISO, and other styles
6

Hurley, Susan F., John J. McNeil, and Con G. Berbatis. "SOURCES OF AUSTRALIAN PHARMACOEPIDEMIOLOGY DATA." Community Health Studies 12, no. 1 (February 12, 2010): 82–96. http://dx.doi.org/10.1111/j.1753-6405.1988.tb00575.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lu, Christine Y. "Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases." Clinical Rheumatology 28, no. 4 (February 4, 2009): 371–77. http://dx.doi.org/10.1007/s10067-009-1102-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Park, Joon Soo, Estie Kruger, and Marc Tennant. "Dispensing patterns of emergency medicines prescribed by Australian dentists from 1992 to 2018 – a pharmacoepidemiology study." International Dental Journal 70, no. 4 (March 13, 2020): 254–58. http://dx.doi.org/10.1111/idj.12562.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

De Oliveira Costa, Juliana, Claudia Bruno, Andrea L Schaffer, Smriti Raichand, Emily A Karanges, and Sallie-Anne Pearson. "The changing face of Australian data reforms: Impact on pharmacoepidemiology research." International Journal of Population Data Science 6, no. 1 (April 15, 2021). http://dx.doi.org/10.23889/ijpds.v6i1.1418.

Full text
Abstract:
ObjectiveA wealth of data is generated through Australia’s universal health care arrangements. However, use of these data has been hampered by different federal and state legislation, privacy concerns and challenges in linking data across jurisdictions. A series of data reforms have been touted to increase population health research capacity in Australia, including pharmacoepidemiology research. Here we catalogued research leveraging Australia’s Pharmaceutical Benefits Scheme (PBS) data (2014–2018) and discussed these outputs in the context of previously implemented and new data reforms. MethodsWe conducted a systematic review of population-based studies using PBS dispensing claims. Independent reviewers screened abstracts of 4,996 articles and 310 full-text manuscripts. We characterised publications according to study population, analytical approach, data sources used, aims and medicines focus. ResultsWe identified 180 studies; 133 used individual-level data, 70 linked PBS dispensing claims with other health data (66 across jurisdictions). Studies using individual-level data focussed on Australians receiving government benefits (87 studies) rather than all PBS-eligible persons. 63 studies examined clinician or patient practices and 33 examined exposure-outcome relationships (27 evaluated medicines safety, 6 evaluated effectiveness). Medicines acting on the nervous and cardiovascular system account for the greatest volume of PBS medicines dispensed and were the most commonly studied (67 and 40 studies, respectively). Antineoplastic and immunomodulating agents account for approximately one third of PBS expenditure but represented only 10% of studies in this review. ConclusionsThe studies in this review represent more than a third of all population-based pharmacoepidemiology research published in the last three decades in Australia. Recent data reforms have contributed to this escalating output. However, studies are concentrated among specific subpopulations and medicines classes, and there remains a limited understanding of population benefits and harms derived from medicines use. The current draft Data Availability and Transparency legislation should further bolster efforts in population health research.
APA, Harvard, Vancouver, ISO, and other styles
10

Claassen, Johann Niklas, and Joon Soo Park. "Examining the dispensing patterns of antipsychotics in Australia from 2006 to 2018 - A pharmacoepidemiology study." Research in Social and Administrative Pharmacy, September 2020. http://dx.doi.org/10.1016/j.sapharm.2020.09.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmacoepidemiology Australia"

1

Zagozdzon, Pawel, and Magdalena Pierucka. "90 The use in of antipsychotic medications and mortality in elderly population in poland: pharmacoepidemiologic study." In Preventing Overdiagnosis Abstracts, December 2019, Sydney, Australia. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/bmjebm-2019-pod.103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography